Why Is AYTU A Strong Buy And Potential Buy Out
Aytu BioScience, Inc.AYTU (OTC:AYTU) is a small-cap stock operating in the pharmaceutical industry dedicated to improving Urological health for men worldwide. The Company addresses problems like insomnia, male infertility, and hypogonadism. Their portfolio of products included Natesto , Zolpimist, and MiOXSYS®
- Aytu BioScience (OTC:AYTU) Enters $1.8 Billion U.S. Prescription Sleep Aid Market with Exclusive License to Zolpimist(NYSE:TM) to Expand Company's Commercial-Stage Product Portfolio
- Natesto is the first FDA-approved intranasal testosterone replacement therapy.
ZOLPIMIST™ (zolpidem tartrate) Oral Spray, the only FDA-approved oral spray zolpidem product indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation and is available both in the US and internationally. Zolpidem tartrate has been shown to decrease the time it takes to fall asleep for up to 35 days in controlled clinical studies.
NATESTO® (testosterone) nasal gel, the only FDA-approved nasally administered testosterone indicated for replacement therapy in adult males with a deficiency or absence of endogenous testosterone due to primary hypogonadism. NATESTO® is a prescription medicine that contains testosterone and is used to treat adult males who have low or no testosterone due to certain medical conditions.
ZOLPIMIST™ (zolpidem tartrate) Oral Spray, the only FDA-approved oral spray zolpidem product indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.
THE MiOXSYS® SYSTEM A novel, rapid in vitro diagnostic semen analysis system with the potential to become a standard of care in the diagnosis and management of male infertility. MiOXSYS is a rapid in vitro diagnostic semen analysis test that accurately measures oxidative stress.
the company will launch The Optimist later this year direct sales force it will be promoting its Pride products Primary Care Clinic Mission and prescribers of sleep aids.
Mr. Disbrow continued, "We believe Zolpimist will serve a large need in insomnia, which affects up to 30% of Americans, while giving our sales representatives another novel product to sell to their primary care physicians. We thank licensor Magna Pharmaceuticals for selecting Aytu BioScience to commercialize Zolpimist and look forward to working with Magna as we build awareness and grow prescription demand for this important, novel product."
Last year, Pfizer’s (PFE) Viagra had worldwide sales of $1.7 billion.
In 2008, Pfizer’s Viagra generated some 1.93 billion U.S. dollars of revenue. Viagra is used primarily to treat erectile dysfunction and pulmonary arterial hypertension. Viagra’s patent protection in the U.S. was prolonged until April 2020.
Eli Lilly & Co (LLY) Cialis is also a product for Erectile Dysfunction and has sold Estimated 2016U.S. sales: $1.469 billion U.S
Considering that Aytu Bioscience Inc (OTCQX:AYTU) is the cheapest in the market for Erectile Dysfunction Products and has 2 FDA approved medicine and more approvals in the pipeline we believe it could be a potential takeover buy one of the Big Pharma Companies mentioned above.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Aytu BioScience, Inc. (OTC:AYTU) , is undervalued. 52 Week High traded around $16 before a split.
CWEB Analyst’s have Reiterates a Buy Rating for Aytu BioScience, Inc. (OTC:AYTU) , and a Price Target of $10 – $20 within 12 months.
A possible Buy Out for (OTC:AYTU) is strongly possible by a big pharma.
Read Full Article and Videos CWEB.com – Trending News, Blog, Shopping
Disclosure: I am/we are long AYTU.